Total tau, p-tau, and Aβ42 are routinely used in the clinical diagnosis of AD (NIA-AA diagnostic criteria for AD11), and protein 14–3-3 is part of the current clinical diagnostic criteria for CJD (revised WHO criteria for CJD)34. The gene discussed is MAPT; the disease is Alzheimer disease.